Exploring the New Aripiprazole Formulation and Its Efficacy

This chapter offers an in-depth look at Asintafi, the recently FDA-approved formulation of Aripiprazole, highlighting dosage recommendations and transition strategies for patients. It also addresses the discussions surrounding its efficacy for acute mania and the absence of approval for bipolar depression.